Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

Withdrawn before enrolling · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining carboplatin, temozolomide, and filgrastim in treating patients who have newly diagnosed or recurrent high-grade glioma.

Key facts

Study ID

NCT00006263

Run by

NYU Langone Health

People needed

0

Starts

1997-11-01

Last updated by the study team

2015-08-05

Who can join

Age: any, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.